Accès gratuit
Med Sci (Paris)
Volume 20, Numéro 10, Octobre 2004
Page(s) 882 - 886
Section M/S revues
Publié en ligne 15 octobre 2004
  1. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy for HIV infection in adults. JAMA 2000; 283 : 381–90.
  2. Gayle HD, Hill GL. Global impact of human immunodeficiency virus and AIDS. Clin Microbiol Rev 2001; 14 : 327–35.
  3. Cock KM, Weiss HA. The global epidemiology of HIV/AIDS. Trop Med Int Health 2000; 5 : A3–9.
  4. Cohen J. Confronting the limits of success. Science 2002; 296 : 2320–4.
  5. Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment for adult HIV infection in 2002 : updated recommendations of the International AIDS Society-USA panel. JAMA 2002; 288 : 222–35.
  6. Furman PA, Fyfe JA, St Clair MH, et al. Phosphorylation of 3’-azido-3’-deoxythymidine and selective interactions of the 5’-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986; 83 : 8333–7.
  7. Hart GJ, Orr DC, Penn CR, et al. Effects of 2’-deoxy-3’-thiacytidine (3TC) 5’-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta and gamma. Antimicrob Agents Chemother 1992; 37 : 918–20.
  8. Spence RA, Kati WM, Anderson KS, et al. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Science 1995; 267 : 988–92.
  9. Gu Z, Quan Y, Li Z, et al. Effects of non-nucleosides inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assay. J Biol Chem 1995; 270 : 31046–51.
  10. Boden D, Markowitz M. Resistance to human immunodeficiency type 1 protease inhibitors. Antimicrob Agents Chemother 1998; 42 : 2775–83.
  11. Quiros-Roldan E, Signorini S, Castelli F, et al. Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy. J Clin Lab Anal 2001; 15 : 43–6.
  12. Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV cohort study. AIDS 1999; 13 : F17–21.
  13. Johnson VA, Brun-Vésinet F, Clotet B, et al. Drug resistance mutations in HIV-1. Top HIV Med 2003; 11 : 215–21.
  14. Wainberg MA, Brenner BG. HIV-1 drug resistance. In : Essex M, et al., eds. AIDS in Africa, 2nd ed. Dordrech : Kluwer Press 2002 : 345–54.
  15. Brenner BG, Wainberg MA. The role of antiretrovirals and drug resistance in vertical transmission. Ann NY Acad Sci 2000; 918 : 9–15.
  16. Gunthard HF, Wong JK, Ignacio CC, et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998; 72 : 2422–8.
  17. Kuritzkes D. Progress in drug-resistance testing in the management of antiretroviral therapy. PRN Notebook 1999; 4 : 14–8.
  18. Larder BA, Kemp SD, Hertogs K, et al. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes : the virtual phenotype (virtual phenotype). Antiviral Ther 2000; 5 : 49 (abstract).
  19. Sheldon JG, Condra JH. Genotypic analysis methods for detection of drug resistance mutations in the HIV-1 proteinase and reverse transcriptase genes. Antiviral Ther 1999; 4 : 135–42.
  20. ONUSIDA/OMS 2003. Le point sur l’épidémie de sida.1-39.
  21. World Health Organization. Safe and effective use of antiretroviral treatments in adults. With particular references to resource limited setting. Geneva : WHO, 2000 : 1-21.
  22. Descamps D, Collin G, Letourneur F, et al. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents : in vitro phenotypic and genotypic analysis. J Virol 1997; 71 : 8893–8.
  23. Loemba H, Brenner B, Parniak MA, et al. Genotypic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against non-nucleoside inhibitors of RT. Antimicrob Agents Chemother 2002; 46 : 2087–94.
  24. Caride E, Hertogs K, Larder B, et al. Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virus Gene 2001; 23 : 193–202.
  25. Loemba H, Brenner B, Parniak MA, et al. Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance. Antiviral Res 2002; 56 : 129–42.
  26. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003; 17 : 1–5.
  27. Eshleman SH, Guay LA, Mwatha A, et al. Characterization of nevirapine resistance mutations in women with subtype A Vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Def Syndr 2004; 35 : 126–30.
  28. Alves AS, Basso CR, Souza RA, et al. Virological efficacy of the people with HIV/AIDS in ARV therapy in accordance with the time of treatment in centre of reference and training in DST/AIDS, Sao Paulo, Brazil. Paris, France : 2nd IAS conference on HIV pathogenesis and treatment, 2003 : 685 (abstract).
  29. Weidle PJ, Downing R, Sozi C, et al. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV drug access initiative-Uganda. AIDS 2003; 17 : S39–48.
  30. Djomand G, Roels T, Ellerbrock T, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d’Ivoire. AIDS 2003; 17 : S5–15.
  31. Laniece I, Ciss M, Desclaux A, et al. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS 2003; 17 : S103–8.
  32. Hogg RS, Yip B, Chan K, et al. Nonadherence to triple combination therapy is predictive of AIDS progression and death in HIV-positive men and women. San Fransisco, USA : 7th Conference on retroviruses and opportunistic infections, 2000 : 73 (abstract).
  33. Amoroso A, Davis CE, Redfield RR. Antiretroviral therapy in resource-limited settings. In : Essex M, et al., eds. AIDS in Africa, 2nd ed. Dordrech : Kluwer Press, 2002 : 322–33.
  34. Liechty CA, Bansberg DR. Doubts about DOT : antiretroviral therapy for resource-poor countries. AIDS 2003; 17 : 1383–7.
  35. Farmer P, Leandre F, Mukherjee JS, et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet 2001; 358 : 404–9.
  36. Hirsch MS, Brun-Vézinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1. Recommendations of an international AIDS society-USA panel. Clin Infect Dis 2003; 37 : 113–28.
  37. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy : the VIRADAPT randomized controlled trial. Lancet 1999; 353 : 2195–9.
  38. Baxter JD, Mayers D, Wentworth DN, et al. Final results of CPCRA 046 : a pilot study of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Antiviral Ther 1999; 4 : 61 (abstract).
  39. Ravela J, Betts BJ, Brun-Vezinet F, et al. HIV-1 protease and reverse transcriptase patterns responsible of discordances between genotypic drug resistance interpretation algorithms. J AIDS 2003; 33 : 8–14.
  40. Götte M, Wainberg MA. Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase. Drug Resist Updates 2000; 3 : 30–8.
  41. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda : HIVNET 012 randomised trial. Lancet 1999; 354 : 795–802.
  42. Van Leth F, Hassink E, Phanuphak P, et al. The 2NN study : a randomised comparative open label trial of first-line antiretroviral therapy with regimens containing either nevirapine, efavirenz, or both drugs combined in addition to stavudine and lamivudine. Boston, USA : 10th Conference on retroviruses and opportunistic infections, 2003 : 176 (abstract).

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.